Business and Organization (Details)			1 Months Ended	12 Months Ended
	May 09, 2022 USD ($) $ / shares shares	Apr. 29, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) facility	Dec. 31, 2022 USD ($) employee $ / shares shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2020 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of sales employees | employee				180
Common Stock, par value (in dollars per share) | $ / shares				$ 0.01	$ 0.01
Fair value of shares included in consideration from GeneDx Holdings				$ 172,000,000	$ 0	$ 0
Gain on sale of GeneDx				$ 18,559,000	0	$ 0
Gain on sale of assets					$ 31,500,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Waterford, Ireland Facility
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities sold | facility			1
Consideration from sale of facility			$ 65,000,000
GeneDx Holdings | Common Class A
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Investment owned (in shares) | shares				80,000,000
Common Stock
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stock price (in dollars per share) | $ / shares	$ 2.44
ModeX
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total aggregate consideration	$ 300,000,000
Common Stock, par value (in dollars per share) | $ / shares	$ 0.01
Shares deposited in escrow (as a percent)	10.00%
Escrow deposit, term	12 months
Business acquisition, equity awards issued	$ 12,400,000
Equity interest issued or issuable, period following closing date	4 years
Escrow period	4 years
ModeX | Former Stockholders
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Business acquisition, equity awards issued	$ 812,792
ModeX | Common Stock
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of shares issued in business combination (in shares) | shares	89,907,310
Fair value of shares included in consideration from GeneDx Holdings	$ 219,400,000
Stock price (in dollars per share) | $ / shares	$ 2.44
Detect Genomix | Milestone Consideration, Tranche One
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shareholder agreement, extension period		1 year
Detect Genomix | Milestone Consideration, Tranche Two
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shareholder agreement, extension period		6 months
Detect Genomix | GeneDx Holdings
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total aggregate consideration		$ 447,000,000
Maximum earnout payment (in shares) | shares		30,900,000
Payments to acquire business		$ 150,000,000
Total upfront consideration transferred		$ 322,000,000
Outstanding shares held (as a percent)		5.00%
Gain on sale of GeneDx				$ 18,600,000
Detect Genomix | GeneDx Holdings | Common Class A
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Common Stock, par value (in dollars per share) | $ / shares		$ 0.0001